This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Farman, C. A. Articles by Kornbrust, D. J. Search for Related Content PubMed PubMed Citation Articles by Farman, C. A. Articles by Kornbrust, D. J. Pubmed/NCBI databases Medline Plus Health Information Immune System and Disorders Social Bookmarking                         What's this?

Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications

Sierra Biomedical, a Division of Charles River Sparks, Nevada, cafarman{at}ucdavis.edu

Doug J. Kornbrust

Sierra Biomedical, a Division of Charles River Sparks, Nevada

Antisense oligodeoxynucleotide compounds (AS ODN) are being developed as therapeutics for various disease indications. Their safety and pharmacokinetics are most commonly evaluated in rodents and nonhuman primates. Traditional AS ODN are short, single strands of DNA, and they target specific mRNA sequences. Plasma clearance of AS ODN is rapid, broad tissue distribution occurs, and elimination is by nuclease metabolism. Structural modifications to AS ODN have been made to enhance their efficacy and improve their safety. A number of class effects are observed with AS ODN that are unrelated to the specific targeted mRNA sequence. Acute effects include activation of the alternative complement pathway and inhibition of the intrinsic coagulation pathway. In monkeys, rodents, and dogs given repeated doses of AS ODN, accumulation of AS ODN and/or metabolites occurs in the form of basophilic granules in various tissues, including the kidney, lymph nodes and liver. A new potential therapeutic application of ODN is that of immune stimulation. Immunostimulatory ODN (IS ODN) are being investigated for use in treating cancer, infectious disease, and allergy. For the development of both AS and IS ODN, primates will continue to be important for safety assessment.

Key Words: Antisense • monkey • oligodeoxynucleotide • immune stimulatory • primate • CpG motif.

Toxicologic Pathology, Vol. 31, No. 1 suppl, 119-122 (2003)
DOI: 10.1080/01926230390174995


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. W. Stief Coagulation Activation by Lipopolysaccharides Clinical and Applied Thrombosis/Hemostasis, April 1, 2009; 15(2): 209 - 219. [Abstract] [PDF]

				J.-H. Wang, B. M. Hendry, and C. C. Sharpe Silencing genes in the kidney: antisense or RNA interference? Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2115 - 2118. [Full Text] [PDF]

				P. Johansen, T. Storni, L. Rettig, Z. Qiu, A. Der-Sarkissian, K. A. Smith, V. Manolova, K. S. Lang, G. Senti, B. Mullhaupt, et al. Antigen kinetics determines immune reactivity PNAS, April 1, 2008; 105(13): 5189 - 5194. [Abstract] [Full Text] [PDF]

				N. Goebl, B. Berridge, V. J. Wroblewski, and P. L. Brown-Augsburger Development of a Sensitive and Specific in Situ Hybridization Technique for the Cellular Localization of Antisense Oligodeoxynucleotide Drugs in Tissue Sections Toxicol Pathol, June 1, 2007; 35(4): 541 - 548. [Abstract] [Full Text] [PDF]

				T. W. Stief Thrombin Generation by Exposure of Blood to Endotoxin: A Simple Model to Study Disseminated Intravascular Coagulation Clinical and Applied Thrombosis/Hemostasis, April 1, 2006; 12(2): 137 - 161. [Abstract] [PDF]